Table 2

Physiological and pharmacokinetic parameters from the subcutaneous tumor homogenate study

ParameteraV− treatment groupsbV+ treatment groups
ControlTNP 30 mg/kgTNP 60 mg/kgControlTNP 30 mg/kgTNP 60 mg/kg
Tumor size [mm3]1878 ± 6261374 ± 10331755 ± 17792389 ± 6592023 ± 4781064 ± 349
Body weight (g)275 ± 50282 ± 41302 ± 7215 ± 37214 ± 42237 ± 19
ss Cp TMZ (μg/ml)48.0 ± 6.054 ± 5.858.7 ± 21.448.0 ± 6.754.3 ± 3.941.0 ± 4.0
ss Ct TMZc (μg/ml)18.8 ± 6.615.1 ± 3.216.5 ± 3.639.5 ± 8.427.5 ± 6.2d19.5 ± 6.7d
ss Ct/Cp TMZ0.39 ± 0.090.28 ± 0.030.30 ± 0.090.83 ± 0.150.51 ± 0.10d0.47 ± 0.11d
ss Cp MTIC (μg/ml)1.0 ± 0.11.1 ± 0.21.0 ± 0.41.0 ± 0.21.3 ± 0.31.0 ± 0.2
ss Ct MTIC (μg/ml)0.49 ± 0.080.47 ± 0.030.52 ± 0.020.97 ± 0.200.45 ± 0.05d0.54 ± 0.10d
ss Ct/Cp MTIC0.50 ± 0.070.44 ± 0.090.57 ± 0.261.02 ± 0.160.38 ± 0.10d0.53 ± 0.07d
  • a ss Cp, steady-state plasma concentration; ss Ct, steady-state whole tumor concentrations. Body weights and tumor volumes are reported from the last day of vehicle or TNP-470.

  • b All values are mean ± SD with n = 4 in all groups except the TNP-470 60 mg/kg group, in which n = 3.

  • c All TMZ and MTIC tumor concentrations reported from the peripheral region of the tumor.

  • d Significantly different than corresponding control group; P < 0.05.